Sarcopenia: Who Benefits Most From Exercise and Nutrition?

Exercise plus nutrition can improve measures of sarcopenia, but the current evidence does not support one universal response story. The most credible subgroup signal is specific: people with confirmed sarcopenia and abnormal BMI showed clearer gains in skeletal muscle mass index (SMI) than people with suspected sarcopenia or normal BMI. That finding concerns muscle mass, not a guarantee of better grip strength, mobility, independence, or longer life.

For older adults trying to preserve muscle, the practical starting point remains resistance-centered exercise paired with protein-focused nutrition. Supplements may have a role, but they do not replace loading the muscle. Biology remains annoyingly unimpressed by a supplement cabinet that never lifts anything.

What the best combined-treatment review found

A 2025 systematic review and meta-analysis by Yang et al. pooled 15 randomized controlled trials of combined exercise and nutrition interventions in sarcopenia-related populations. Across its four pooled outcomes, the combined approach improved results overall. The size and consistency of those effects differed substantially by endpoint.

Handgrip strength increased by a mean 1.38 kg across 12 studies, comparing 421 intervention participants with 427 control participants. The result varied greatly among trials: heterogeneity was high (I² = 83%). A pooled improvement can coexist with a mixed real-world experience when programs, participants, nutritional strategies, and baseline impairment differ.

The muscle-mass result was more consistent. Five studies, with 188 intervention participants and 173 control participants, found an SMI mean difference of 0.18, with lower heterogeneity (I² = 29%). SMI is a body-composition measure, so it is useful but incomplete. More muscle mass does not automatically establish fewer falls, greater independence, or better quality of life.

The evidence supports combined treatment on average. It does not establish that every older adult will gain the same amount of strength or function.

The subgroup result worth taking seriously

Yang et al.'s subgroup analyses were sharper for SMI than for handgrip strength. Participants with abnormal BMI had an SMI mean difference of 0.19. The normal-BMI subgroup had a mean difference of 0.08 and did not reach statistical significance. People with confirmed sarcopenia had an SMI mean difference of 0.18, while participants with suspected sarcopenia showed no clear SMI benefit.

These results make clinical sense as a basis for assessment, not as a license for overconfident targeting. Confirmed sarcopenia may identify people with more measurable room for improvement, and abnormal BMI can signal body-composition issues that BMI alone obscures. But the review used suspected versus confirmed sarcopenia as a proxy for severity. It did not prove that a particular degree of disease causes a larger response.

The age analysis is even less ready for prime time. The only age subgroup with a clear handgrip result was the single study in participants younger than 65, which reported a mean difference of 4.67 kg. Among participants aged 65 or older, the pooled handgrip mean difference was 1.03 kg and showed no clear effect. One trial cannot establish that younger adults generally respond better; it establishes that one trial had a larger result.

Why resistance training remains the base

A 2025 network meta-analysis by Zhao et al., comparing exercise and nutrition strategies under EWGSOP and AWGS diagnostic frameworks, reaches a compatible practical conclusion. Exercise and nutrition both matter, but the intervention should fit the diagnosis and the outcome being targeted. Resistance-oriented exercise has the clearest role as the treatment backbone, while nutrition supports adaptation rather than substituting for training.

Direct trial evidence also shows that frail institutionalized adults can improve with appropriately loaded exercise. In a 2025 randomized trial, Pan et al. assigned 61 nursing-home residents aged 65 to 89 with pre-frailty and sarcopenia to 12 weeks of the Otago Exercise Program plus resistance training three times weekly or to usual daily activities. Compared with controls, the exercise group improved SMI (5.79 versus 5.43; p = 0.037) and skeletal muscle mass (21.8 versus 19.5; p = 0.017), alongside reported improvements in physical function and frailty.

That trial supports adding resistance work when a baseline program is otherwise low load. It did not test a nutrition intervention, so it cannot answer whether nursing-home residents respond especially well to combined exercise plus nutrition. Setting-specific claims remain limited because related subgroup estimates often draw on only one or two studies.

Nutrition should be targeted, not magical

Protein-focused nutrition fits naturally with resistance training because building or retaining muscle requires both an exercise stimulus and adequate nutritional support. Still, "nutrition" is a category, not a single treatment. The available evidence is stronger for protein-centered strategies alongside exercise than for a universal micronutrient prescription.

A 2021 network meta-analysis by Cheng et al. examined vitamin D strategies in randomized sarcopenia trials. Vitamin-D-containing strategies showed no clear overall benefit for gait speed or muscle mass, although chair-stand time improved. Vitamin D may therefore be appropriate when a person's clinical context supports it, but it is not a stand-alone sarcopenia treatment.

Several observational studies point to groups that deserve especially careful nutritional assessment. A 2025 cross-sectional study by Eksteen et al. found concerns about low muscle mass and protein intake among adults older than 65 after previous bariatric surgery. The study identifies a plausible high-risk group; it does not show that these adults gain more from a combined program.

Likewise, a cross-sectional study of Chilean adults aged 65 and older by Crovetto Mattassi et al. associated sarcopenia with poorer nutritional status. Other observational work has linked dietary inflammatory index with sarcopenia development, described a sarcopenic-obesity phenotype index, and associated pancreatic exocrine insufficiency with sarcopenia in older adults with type 2 diabetes. These associations help identify circumstances where clinicians may need to look harder for nutritional risk, malabsorption, or adverse body composition. They do not prove a treatment-response advantage.

Where the evidence breaks down

The combined-treatment evidence has real limitations. In Yang et al.'s review, only 8 of 15 trials used blinding procedures. Outcome-assessor blinding was often unclear, about half of studies had unclear selective-reporting risk, and roughly 80% had possible detection-bias concerns. These weaknesses matter most for outcomes with high inconsistency, including handgrip strength.

Subgroup analyses add another layer of uncertainty. They can generate useful hypotheses, but the estimates become unstable when only a few trials contribute. This is why the SMI signals for confirmed sarcopenia and abnormal BMI deserve attention without becoming a rigid triage rule. The evidence does not show that these groups improve more on every outcome, nor that they should automatically receive priority over an older adult with a different but urgent clinical risk.

Diagnostic criteria also vary. Zhao et al. compared evidence using EWGSOP and AWGS frameworks, and different definitions can change who qualifies as having sarcopenia. A program's apparent success may partly reflect the population selected and the endpoint measured rather than a universally superior protocol.

A practical evidence-based approach

For an older adult with sarcopenia or a credible risk of it, start by confirming the diagnosis and clarifying the target: muscle mass, strength, physical function, frailty, or a combination. Then build a resistance-centered exercise plan appropriate to health status and capability, and assess whether protein intake and overall nutrition can support it.

• Give the greatest weight to confirmed sarcopenia, body composition and nutritional risk when personalizing care.
• Use abnormal BMI as a cue to assess muscle and fat distribution more carefully, not as a diagnosis by itself.
• Consider vitamin D as a selective adjunct when clinically indicated; do not expect it to replace training or protein-focused nutrition.
• Screen carefully after bariatric surgery and in older adults with diabetes or suspected pancreatic exocrine insufficiency, where nutritional problems may be easier to miss.

The present verdict is deliberately narrow: combined exercise and nutrition appears to improve sarcopenia-related outcomes, with the clearest subgroup evidence for SMI gains in people with confirmed sarcopenia and abnormal BMI. Resistance training plus adequate nutrition is a sensible default. Claims about universal strength gains, age-based super-responders, or a supplement that solves sarcopenia run ahead of the trials.